SG/PUT/ABBVIE/180/0.1/21.03.25 Share Price

DE000SU6QVQ8

Market Closed - Boerse Frankfurt Warrants 20:36:44 28/06/2024 BST
1.63 ^EUR	-3.55%

Current month	-27.88%
1 month	-37.07%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie - Introducing Alle Payment Plans, Powered by Cherry	06-28	AQ
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	PR

More news

Quotes 5-day view

Date	Price	Change
28/06/24	1.63	-3.55%
27/06/24	1.69	+11.18%
26/06/24	1.52	-3.18%
25/06/24	1.57	+6.80%
24/06/24	1.47	-7.55%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 08:36 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	ABBVIE INC.
Issuer	Société Générale
WKN	SU6QVQ
ISIN	DE000SU6QVQ8
Date issued	08/01/2024
Strike	180 $
Maturity	21/03/2025 (265 Days)
Parity	10 : 1
Emission price	2.35 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	2.63 €
Lowest since issue	1.29 €
Spread	0.03 €
Spread %	1.85%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company